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Summary To study abnormalities of the FHITgene in human hepatocellular carcinoma (HCC), eight liver cancer cell lines, 18 matched
tumorous and non-tumorous tissues from patients with HCC and three normal liver tissues were analysed by microsatellite polymorphism
analysis and reverse transcription of FHITmRNA followed by polymerase chain reaction (PCR) amplification and sequencing ofthe products.
No loss of heterozygosity at chromosome 3p14.2 as defined by markers D3S1300 and D3S1312 was detected in any of the specimens. In
addition, a normal transcript of the gene without any sequence change was found to be expressed in all the cell lines, 17 of the 18 tumorous
and all 21 non-tumorous liver tissues tested. Although five out of eight liver cancer cell lines (62.5%), 12 out of 18 HCC tissues (66.7%) and
8 out of 18 paired non-tumorous liver tissues (44.4%) displayed abnormal faint bands of smaller size, sequence analysis revealed that they
were aberrant FH/Ttranscripts lacking three or more exons and might represent alternatively spliced transcripts only. In conclusion, these
studies indicate that abnormalities of the FHITgene transcripts occur in a fairly high frequency of tumorous and non-tumorous liver tissues.
However, it might not be causally related to the hepatocarcinogenesis.
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Hepatocellular carcinoma (HCC) is one of the most common
human malignancies in the world, especially in areas such as China
and sub-Saharan Africa (Okuda, 1992; Wright et al, 1992). It
usually carries a grave prognosis. The precise aetiology ofHCC is
not yet clear, however it is well known that HCC is frequently
associated with a background of chronic liver disease (Beasley et
al, 1981). Predisposing factors include hepatitis B virus orhepatitis
C virus infection and aflatoxinBI exposure (Okuda, 1992; Wright
etal, 1992; Chen, 1993). Hepatocarcinogenesis is therefore consid-
ered as a multifactorial and multistep process thatincludes the acti-
vation of oncogenes and the inactivation of tumour-suppressor
genes (Ding and Habib, 1994; Sugimura, 1992).
Recently, the FHITgene (fragile histidine triad gene), a candi-
date tumour-suppressor gene, was identified at 3pl4.2 (Ohta et al,
1996). The gene spans the t(3;8) translocation breakpoint of
familial renal cell carcinoma and contains the FRA3B fragile site
(Cohen et al, 1979; Paradee et al, 1995; Ohta et al, 1996). It is the
target ofhomozygous deletions in various human cancercell lines,
such as colon and gastric cancer cell lines (Kastury et al, 1996). In
addition, aberrant transcripts of the FHIT gene have been identi-
fied in 50% ofprimary gastrointestinal tumours (Ohta et al, 1996),
80% ofsmall-cell lung cancers and at least 40% ofnon-small-cell
lung cancers (Sozzi et al, 1996a).
In the current study, we examined 18 cases of HCCs and eight
liver cancer cell lines for the presence of FHIT abnormalities.
Microsatellite polymorphism analysis using primers at chromo-
some 3pl4 and reverse transcription (RT) of FHIT mRNA
followed by the polymerase chain reaction (PCR) and sequencing
ofthe products were performed.
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MATERIALS AND METHODS
Patients
Eighteen HCC tissues and their corresponding normal liver tissues
were obtained from patients who had undergone surgery at the
Taipei Municipal Jen-Ai Hospital. Informed consent was obtained
from all patients. Tumours were dissected to eliminate normal
tissue contamination. All the specimens were frozen immediately
after surgical resection and stored in liquid nitrogen before
testing. All cancerous and non-cancerous tissue specimens were
confirmed by pathological examination. The clinicopathological
features of each patient were reviewed and recorded. There were
12 men and six women. The mean age ofpatients at resection was
60.4 years. Except for one patient (5.6%), who was positive for
both serum hepatitis B virus surface antigen (HBsAg) and anti-
hepatitis C virus antibody (anti-HCV antibody), serum HBsAg
was positive in 10 out of the 18 patients (55.6%) and serum anti-
HCV antibody was positive in the remaining seven patients
(38.9%). A total of 12 out ofthe 18 patients (66.7%) had cirrhosis
and the other six patients had chronic hepatitis (33.3%).
Three normal liver tissues, obtained from colon cancer patients
who had undergone partial hepatectomy for liver metastasis, were
also studied. These three cases were all negative for both serum
HBsAg and anti-HCV antibody. A panel of six human HCC cell
lines (Hep 3B, HA22T, HCC36, Tong, SK-Hep-l and HuH-7) and
two human hepatoblastoma cell lines (Hep G2 and HuH-6), were
included in this study (Doi, 1976; Fogh et al, 1977; Aden et al,
1979; Nakabayashi et al, 1982).
Microsatellite polymorphism analysis
To detect allelic losses, a PCR-based approach as described by
Kastury et al was performed (1996). Two loci, D3S1300 (within
the FHITgene) and D3S1312 (centromerically flanking the FHIT
gene) were selected (Druck et al, 1995; Kastury et al, 1996; Ohta
et al, 1996; Sozzi et al, 1996a).
417418 Y-J Chen etal
Table 1 Aberrant transcripts observed in HCC
Case Age Sex HBsAg HCV Cirrhosis Abnormal transcript LOH
(years)
Non-tumour Tumour
1 77 M + - - Ex 4-8 loss Ex4-8 loss -
2 67 M - + - - Ex4-7 losswith -
Alu insertion
3 74 F - + + Ex4-8 loss Ex 5-8 loss -
4 37 M + - - - -
5 53 M + - + Ex4-8 loss Ex 5-7 loss -
6 57 M + - - - -
7 76 F - + + Ex 5-7 loss -
8 51 M + - + Ex4-6 loss Ex4-6 loss -
9 62 M + - + Ex4-6 loss Ex4-6 loss -
10 60 F + - + Ex4-6 loss Ex 5-7 loss -
11 20 M + - - - Ex4-8loss -
12 47 F + - - - - N
13 71 F - + + - Ex5-8loss N
14 50 M - + + Ex4- loss -
15 62 M + + + - Ex 5-7 loss -
16 67 F - + + - -
17 72 M + - + - Ex4-8loss N
18 83 M - + + - Ex4- loss -
In addition to the aberrant transcripts indicated above, a normal-sized transcript was present in all the tumorous and non-tumorous tissues examined except in
the tumorous tissue of case 1. Loci analysed for LOH were D3S1300 and D3S1312. HBsAg, hepatitis B virus surface antigen; HCV, anti-hepatitis C virus
antibody; Cir, cirrhosis; LOH, loss of heterozygosity; Ex, exon; M, male; F, female; Alu, Alu repeat; N, not informative.
RNA extraction, reverse transcriptase-polymerase
chain reaction (RT-PCR) and sequence analysis
The transcripts of the FHIT gene were examined using RT-PCR.
RNA was purified from tumorous and non-tumorous liver tissues
and cell lines, and cDNA was generated from RNA as described
previously (Chen et al, 1997). Nested PCR amplifications were
carried out using primers, flanking the full coding sequence ofthe
FHIT cDNA, as described previously (Ohta et al, 1996). All the
reactions were performed at least twice and for verification ofthe
integrity of the RNA samples, control RT-PCR amplifications
using primers specific for glyceraldehyde 3-phosphate dehydro-
genase (G3PDH) gene were performed (Nobori et al, 1994).
Procedures for sequencing of PCR products have been described
previously (Chen et al, 1997).
FHIT
Normal transcript
1 2 3 4 10
Aberranttranscript
Il21 3_4
T5, Ti 0, Ti 5; N7;Tong
Ill 2 3 4
T3,T13
1ll2 13
T8, T9; N8, N9, N10; Sk-Hep-1, HuH-7, HuH-6
Tl, T1i,T17, T18; N1, N3, N5, N14; HA22T
RESULTS AND DISCUSSION
To study abnormalities ofthe FHITgene, we first examined chro-
mosome 3p14.2 by microsatellite polymorphism analysis. A total
of 15 out of 18 (83.3%) cases were informative for at least one of
the two loci examined and none of them revealed LOH (data not
shown). Although small deletions and rearrangements could not
be excluded, the results suggest that the chromosome 3pl4.2
region as defined by markers, D3S1300 and D3S1312 was intact
in both alleles in these cases.
The expressions ofthe FHITtranscripts were then examined by
RT-PCR amplification. Except in the tumorous tissue of case 1,
normal-sized bands were detected readily in all the tissues and the
cell lines that we examined. However, faint bands of smaller size
were also seen in 12 out ofthe 18 tumorous (66.7%) and 8 out of
the 18 non-tumorous (44.4%) liver tissues (P > 0.05, McNemar's
test, X2 = 1.12, d.f. = 1). In addition, five out of the eight liver
tumour cell lines also revealed abnormally smaller bands.
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Figure 1 A schematic representation of the aberrant transcripts detected in
the HCC specimens and liver cancer cell lines. The coding exons of the FHIT
gene are in grey colors and a segment of Alu repeat is indicated by oblique
lines. Numbers in the bars, FHlTexons; arrowheads, abnormal junctions
between exons 4 and 8, exons 4 and 9, exons 3 and 7, exons 3 and 9, and
exon 3, Alu repeat and exon 8; T, tumorous; and N, non-tumorous liver
tissues; numbers following T or N are case numbers. *, Coding exons; O,
non-coding exons; 0, Alu sequence
Subsequently, the RT-PCR products were examined by
sequence analysis. For the normal-sized products, no variations
were detected. However, sequence analysis of the smaller bands
revealed that they represented aberrant FHIT transcripts. A
detailed description ofthese aberrant transcripts is summarized in
Figure 1 and Table 1. In brief, five different types ofaberrant tran-
scripts with loss of various exons from 4-8 were observed: prod-
ucts lacking exons 5-7, 5-8, 4-6,4-8 and aproduct lacking exons
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4-7 and an insertion ofa 138-bp Alu sequence. As the fusion func-
tions all coincided exactly with the splice sites, these aberrant tran-
scripts might represent alternatively spliced products.
Six cases (cases 1, 3, 5, 8, 9 and 10) revealed aberrant tran-
scripts in both tumorous and non-tumorous liver tissues. Three of
them had the same abnormal pattern of the aberrant transcripts
between tumorous and non-tumorous tissues; however, in the other
three cases (cases 3, 5 and 10), the patterns were different between
the paired samples (Table 1). Whereas six cases had aberrant tran-
scripts only in their tumorous tissues, we also found two cases
(cases 7 and 14) showing an aberrant transcript in their non-
tumorous liver tissues only (Table 1).
Taken together, our results suggested that abnormalities of the
FHIT gene might not be related to hepatocarcinogenesis. First,
although in agreement with previous reports of other human
malignancies (Negrini et al, 1996; Ohta et al, 1996; Sozzi et al,
1996a,b), aberrant transcripts of the FHIT gene were frequently
detected in the tumorous liver tissues, they also existed in the non-
tumorous liver tissues. Recently, Boldog et al reported the pres-
ence of the aberrant FHIT transcripts in the normal fetal brain
cDNA andconcluded that the alternative splicing definitely occurs
in normal human tissues (Boldog et al, 1997). This is consistent
with our findings and may explain the currently and most previ-
ously reported abnormal FHITtranscripts. Therefore, it is possible
that the FHIT gene is simply located near to but is not the true
'target' that drives a clonal selection process (Thiagalingam et al,
1996). Second, in 17 out ofthe 18 tumorous livertissues examined
in this study, a normal-sized RT-PCR product, containing the
complete coding region of the FHITgene, was observed. In addi-
tion, sequence analysis revealed that they were all intact. Ohta et
al. (1996) also detected full-length RT-PCR products in nearly all
cases showing aberrant transcripts but suggested that these might
have resulted from the presence of contaminating non-neoplastic
cells. However, because the normal RT-PCR products were always
present at a robust level, and the normal products were also
observed in all eight liver tumour cell lines, we believe that these
normal products are derived from neoplastic cells. Third,
according to the Knudson's two-hit model for inherited and
sporadic forms of retinoblastoma, tumour-suppressor genes can
usually be inactivated by deletion ofone allele by various mecha-
nisms, and inactivation ofanother allele by mutation, loss or other
mechanisms (Knudson, 1971; Lasko et al, 1991). Reviewing the
literature, in HCC allele losses have been documented on chromo-
somes 1, 4, 5, 8, 10, 11, 13, 16, 17 and 22; however, no such
changes have ever been reported on chromosome 3 (Ding and
Habib, 1995). Sozzi et al (1996a)reported a92% and a63% loss of
one FHIT allele at loci D3S1300 and D3S1312 in primary lung
tumours respectively, but, in this study, we did not detect any
allelic loss at either loci in any of the HCC tissues that we exam-
ined. Therefore, although more loci should be studied to define the
possible small deletions and rearrangements, we believe that the
FHIT gene might not be involved causally in hepatocarcinogen-
esis. Fourth, the Fhit protein is a typical dinucleoside 5',5"'p1, P3-
triphosphate (Ap3A) hydrolase that catalyses the hydrolysis of
dinucleoside polyphosphates with Ap3A as the preferred substrate
(Huang et al, 1995; Bames et al, 1996; Druck et al, 1997).
Although Ap3A has potential significance in the response to
different kinds of stress, blood platelet function, vasomotor
activity and hepatic function control (Bernet et al, 1991), no strong
evidence has been shown that it may contribute to carcinogenesis
(Bamnes et al, 1996).
HCC has been shown to be closely related to chronic HBV or
HCV infection and cirrhosis has been recognized as a precan-
cerous lesion (Beasley et al, 1981; Okuda, 1992; Wright et al,
1992; Chen, 1993). In this study, irrespective of HBV or HCV
infection, the non-tumorous liver tissues contained a fairly high
frequency (44.4%) ofabnormal FHITtranscripts. The FHITgene,
containing a common fragile region, FRA3B, is susceptible to the
breakage caused by physical or chemical carcinogens (Paradee et
al, 1995). As liver plays a major role in the metabolism of most
drugs or toxins, and several carcinogens, such as 2,3,7,8-tetra-
chlorodibenzo-p-dioxin, have been proved to regulate the expres-
sion of a number of genes involved in cell growth control by
activities on their promoters (Lee et al, 1996), it is possible that
similar effects could result in the high frequency of change in the
FHIT gene in the chronically damaged (tumorous or cirrhotic)
liver tissues.
In conclusion, these studies indicate that abnormalities of the
FHIT gene transcripts occur in a fairly high proportion of
tumorous and non-tumorous livertissues. However, it might notbe
causally related to the hepatocarcinogenesis. To clarify further the
molecular basis of FHIT fragility and its involvement in human
cancers, additional evaluations of tumours and normal tissues, as
well as complete sequencing of the specific breakpoints, are
needed.
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